Browsing Tag
Small cell lung cancer
19 posts
Genprex begins dosing of phase 1/2 trial of REQORSA, Tagrisso combo
Genprex has dosed the first patient in the Acclaim-1 phase 1/2 clinical trial of REQORSA immunogene therapy candidate…
March 6, 2022
Amgen secures breakthrough therapy designation for sotorasib in China
Amgen has achieved a major milestone in the global development of its investigational KRAS G12C inhibitor, sotorasib, with…
January 31, 2021
Blueprint Medicines strikes $1.7bn worth deal with Roche for pralsetinib
Swiss pharma giant Roche and US precision therapy company Blueprint Medicines have entered into a worldwide licensing and…
July 15, 2020
Selpercatinib FDA approval : Lilly’s therapy approved for treatment of lung and thyroid cancers with RET alteration
Selpercatinib FDA approval : The US Food and Drug Administration (FDA) has approved Eli Lilly and Company’s Retevmo…
May 9, 2020
Lilly bags Retevmo FDA approval for RET-driven lung and thyroid cancers
Retevmo FDA approval : Eli Lilly and Company (Lilly) has secured approval from the US Food and Drug…
May 9, 2020
Roche’s Tecentriq secures FDA approval for small cell lung cancer treatment
Roche’s subsidiary, Genentech, has announced a significant breakthrough with the US Food and Drug Administration (FDA) approval of…
March 30, 2019
Pfizer’s Lorbrena receives FDA approval for advanced lung cancer treatment
Pfizer Inc., a leading US pharmaceutical company, has secured approval from the US Food and Drug Administration (FDA)…
November 3, 2018
Bristol-Myers Squibb’s Opdivo fails to meet key endpoint in small cell lung cancer trial
Bristol-Myers Squibb’s cancer drug Opdivo (nivolumab) has failed to meet the primary endpoint in the Phase 3 CheckMate…
October 15, 2018
PharmaMar’s lurbinectedin granted orphan drug designation by FDA for small cell lung cancer treatment
Spanish pharmaceutical company PharmaMar has announced that its cancer drug, lurbinectedin, has received orphan drug designation from the…
August 5, 2018